Detalhe da pesquisa
1.
Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.
J Clin Oncol
; 23(30): 7697-702, 2005 Oct 20.
Artigo
Inglês
| MEDLINE | ID: mdl-16186597
2.
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
J Clin Oncol
; 20(22): 4420-7, 2002 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12431963
3.
Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies.
Invest New Drugs
; 21(4): 445-52, 2003 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-14586212